Disse symptomer var alvorlige hos 2, 0% af de patienter, der fik efavirenz 600 mg dagligt, og hos 1, 3% af de patienter, der fik kontrolregimer.
These symptoms were severe in 2.0% of patients receiving efavirenz 600 mg daily and in 1.3% of patients receiving control regimens.